Table 3 Drop in SF-36 and CLDQ-HCV HRQoL scores from antiviral baseline to end of ATV treatment, and at the 24-week post-treatment follow-up by treatment group

SF-36v2 acute

Physical functioning

−5.2 (−6.1, −4.4)

4.8 (−5.4, −4.2)

0.05

−2.2 (−3.1, −1.4)

−1.6 (−2.2, −1.0)

0.08

Role-physical

−4.7 (−5.7, −3.8)

−5.5 (−6.2, −4.8)

−0.08

2.4 (−3.3, −1.4)

−2.2 (−2.9, −1.6)

0.02

Bodily pain

−4.6 (−5.6, −3.7)

−4.8 (−5.5, −4.1)

−0.02

2.3 (−3.4, −1.3)

−1.7 (−2.4, −1.0)

0.06

General health

−3.8 (−4.5, −3.0)

−2.9 (−3.4, −2.3)

0.11

2.3 (−3.1, −1.4)

−1.8 (−2.4, −1.2)

0.06

Vitality

−6.0 (−7.0, −5.1)

−6.1 (−6.7, −5.4)

−0.00

−2.1 (−3.0, −1.2)

−1.4 (−2.1, −0.8)

0.07

Social functioning

−5.3 (−6.3, −4.3)

−6.5 (−7.3, −5.8)

−0.12

2.5 (−3.5, −1.6),

−2.2 (−2.9, −1.5)

−0.12

Role-emotional

−5.3 (−6.5, −4.0)

−6.8 (−7.7, −5.8)

−0.11

−3.1 (−4.2, −2.0)

−2.8 (−3.7, −1.9)

0.03

Mental health

−5.8 (−6.7, −4.9)

−5.3 (−6.0, −4.6)

0.05

−2.1 (−3.0, −1.1)

−1.7 (−2.4, −1.1)

0.07

PCS^a

−5.8 (−6.6, −5.0)

−6.2 (−6.8, −5.6)

−0.05

−2.8 (−3.6, −1.9)

−2.3 (−2.8, −1.7)

0.03

MCS^a

−6.3 (−7.2, −5.4)

−6.4 (−7.1, −5.8)

−0.02

−2.6 (−3.5, −1.7)

−2.1 (−2.7, −1.5)

0.06

CLDQ-HCV

Overall

−0.6 (−0.7, −0.5)

−0.6 (−0.6, −0.5)

0.02

−0.3 (−0.4, −0.2)

−0.2 (−0.3, −0.2)

0.06

Activity

−5.6 (−6.3, −4.8)

−5.6 (−6.2, −5.1)

−0.01

−1.9 (−2.7, −1.2)

−1.8 (−2.3, −1.3)

0.02

Emotion

−4.8 (−5.7, −3.8)

−4.5 (−5.1, −3.9)

0.03

−1.9 (−2.8, −1.0)

−1.8 (−2.4, −1.1)

0.02

Systemic symptoms

−4.0 (−4.6, −3.3)

−4.0 (−4.4, −3.5)

−0.00

−2.3 (−3.0, −1.6)

−1.7 (−2.2, −1.3)

0.09

Worry

−2.5 (−3.4, −1.6)

−1.8 (−2.4, −1.2)

0.07

−1.7 (−2.7, −0.7)

−0.9 (−1.6, −0.2)

0.08